Clinical Trial Update: Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) [Phase 2]

View source ↗

Summary

MBX Biosciences is conducting a Phase 2 trial to evaluate the efficacy and dose response of Imapextide (STEADI) for postbariatric hypoglycemia, and the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postbariatric Hypoglycemia

Drugs mentioned

• Imapextide (Imapextide)

Snippet

Sponsor: MBX Biosciences | Conditions: Postbariatric Hypoglycemia | Phase 2 | Status: RECRUITING